A further tumour agnostic basket trial, denoted FUZE (NCT03834220) is currently assessing objective response rate to Debio-1347 in biliary, urothelial and solid cancers (including breast cancers) with FGFR1–3 fusions or rearrangements, based on encouraging phase 1 data. Here, FGFR1 is linked to breast cancer.